Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.
1 report, 1 independent
Updated Aug 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Barclays dropped its target price on Pilgrim’s Pride shares on November 1, 2026.
- Barclays lifted its share target for Strategy on October 1, 2026.
- Multiple major banks, including Citigroup, UBS, Bank of America, and Barclays, have issued updated price targets and ratings.
- Barclays, Citigroup, and Raymond James Financial issued rating updates for Alaska Airlines Group on October 23, 2026.
- ISI (Twist Bioscience) was listed on the Nasdaq stock exchange, and Barclays raised its price target on the company on July 9, 2026.